TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05375708

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: Patients will receive a single fraction of 15 Gy to each of the macroscopic tumor sites including the primary tumor if still in situ. All lesions are treated. The treatment will be delivered in an image-guided way, either on a conventional linear accelerator (LINAC) or a MR-LINAC, whichever has the best targeting according to the treating radiation oncologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
Description: CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
Description: CAP + bevacizumab (following CAPOX-B) Bevacizumab 7.5mg/kg i.v. on day 1 and 1250 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is \<70 years and 1000 mg/m2 of capecitabine, orally twice daily on days 1-14 if age is higher than 70 years. CAP + bevacizumab is repeated every three weeks.~5-FU/LV + bevacizumab (following FOLFOX-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. bolus 5FU 400 mg/m2 all on day 1. Followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~5-FU/LV + bevacizumab (following FOLFOXIRI-B) Bevacizumab 5.0mg/kg i.v. together with leucovorin 400 mg/m2 i.v. all on day 1. Followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours. 5-FU + bevacizumab is repeated every two weeks.~When S1 is used a replacement for fluoropyrimidine therapy it is administered in a dose of 30mg/m2 twice daily on days 1-14. S1 is repeated every three weeks.
Study: NCT06418308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Spinal Mixture
Description: Standardized spinal mixture of 10.25 mg hyperbaric bupivacaine, and 0.125 mg morphine.
Study: NCT05271383

Intervention type: DEVICE
Intervention: Orthognathic surgery using Global D's implants.
Description: Major or minor participants who will be treated by an orthognathic surgery with ORTRAUTEK® or MINITEK® implant(s).
Study: NCT06220318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C019199
Description: The C019199 will be taken orally, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administrated with intravenous infusion, 200mg, every 3 weeks.
Study: NCT06095011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UpRight Go
Description: The UpRight Go posture trainer is a commercially available biofeedback sensor that externally attaches to the wearer via a necklace or silicon adhesive. It vibrates when it senses that the wearer is slouching and connects to a smartphone application which sets daily goals, tracks usage, and provides assistance and support. It complies with International Electrotechnical Commission (IEC) standards.
Study: NCT06631989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0922-FU
Description: Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0922-FU
Description: Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WSD0922-FU
Description: Procedure: Biospecimen Collection - blood samples Undergo collection of blood samples~Procedure: Computed Tomography and/or Magnetic Resonance Imaging Undergo CT and/or MRI~Drug: WSD0922-FU Given PO
Study: NCT06631963

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Emotional Awareness and Expression Therapy
Description: Emotional Awareness and Expression Therapy (EAET) is a form of psychotherapy designed to help individuals identify, process, and express emotions that may be linked to physical symptoms or chronic pain. It emphasizes the role of unresolved emotional experiences, such as trauma or interpersonal conflicts, in contributing to physical distress. Through EAET, patients learn to connect their emotions to their physical symptoms, express those emotions in a healthier way, and ultimately reduce both emotional and physical suffering. This therapy has been shown to be effective in treating conditions such as chronic pain, irritable bowel syndrome, and fibromyalgia.
Study: NCT06630208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: The experimental group will undergo a 5-day consecutive myofascial release treatment, administered as Osteopathic Manipulative Treatment (OMT), with each session lasting a maximum of 15 minutes. The treatment will consist of three phases targeting the entire mediastinum: Thoracic Inlet (Indirect) Myofascial Release, Rib Raising with continued stretch of the paraspinal muscles to the L2 vertebral level, and Soft Tissue Cervical Paraspinal Muscle Stretch with Suboccipital Muscle Release. Participants will be positioned in a supine posture to enhance diaphragmatic excursion, with each session following a fixed, prearranged sequence of these techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Following the 3 phases of myofascial release, breathing exercises will be done for patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment
Description: Patients will take pharmacological treatment prescribed by the cardiologist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological treatment
Description: Patients will take pharmacological treatment prescribed by the cardiologist.
Study: NCT05349864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment A
Description: PF-07284890 tablet by mouth while fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment A
Description: PF-07284890 tablet by mouth while fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment B
Description: PF-07284890 tablet after low fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment B
Description: PF-07284890 tablet after low fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment C
Description: PF-07284890 tablet after high fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07284890 Treatment C
Description: PF-07284890 tablet after high fat meal
Study: NCT04286022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speed Loss 20% Strength Training
Description: Strength training based on the control of speed loss in execution.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Rest Time Strength Training
Description: Strength training based on a protocol that includes reduced rest times between sets.
Study: NCT05605197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U87 CAR-T
Description: Subjects will be pretreated with cyclophosphamide 250\~500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\~6 patients.
Study: NCT06565091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements of physiological parameters of the anterior chamber
Description: Acquisition by the investigational device
Study: NCT04763356

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Care at Home with NP follow up
Description: In the SCH-NP group all participants will report their CIPN related symptoms daily via the app, website or phone tree. Any concerning symptoms will trigger a call back from a nurse practitioner who will use a consensus and evidence based algorithm to prescribe therapies for the CIPN symptoms.
Study: NCT06565091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurements of the Axial biometry
Description: Acquisition by the investigational device
Study: NCT06526234

Intervention type: DEVICE
Intervention: MRI
Description: MR enterography
Study: NCT06357572

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin generation assay (EnzySystem HemA version A - whole blood)
Description: Whole blood obtained by venipuncture is immediately tested with the EnzySystem HemA version A), before and 0, 30, 120 and 240 minutes after administration of FEIBA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin generation assay (Ceveron s100 (Technoclone) - fresh plasma)
Description: Whole blood is centrifuged to obtain plasma. The fresh plasma is tested using the Ceveron s100.

Intervention type: DIAGNOSTIC_TEST
Intervention: Additional coagulation tests
Description: Plasma samples are frozen for later coagulation testing. The following tests are performed:~Factor VIII activity von Willebrand Factor antigen levels von Willebrand Factor ristocetin activity levels Prothrombin Fragment 1+2 levels ADAMTS13 activity FVIII antigen levels Nijmegen Hemostasis Assay
Study: NCT06342804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 2 tablets, fasted
Description: 2 tablets (256 mg), fasted
Study: NCT05312541

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: pre emptive local anaesthetic wound infiltration
Description: Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pre emptive local anaesthetic wound infiltration
Description: Before skin incision by 15 min the surgeon will infiltrate the wound by syringe containing 20 ml mixture of (10 ml xylocaine 2%and 10 ml bupivacaine 0. 5%) in both groups
Study: NCT04570475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants will receive vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: multivitamin
Description: Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multivitamin
Description: Participants will receive placebo+multivitamin or vitamin D+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo+multivitamin for 3 weeks. At the end of 3 weeks they will complete an online or paper questionnaire and blood work will be done.
Study: NCT06053788

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PocDoc
Description: Point of care digital lipid test
Study: NCT06458127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-palliative care visit
Description: Participants will meet with a specialty palliative care clinician for a video-consultation once a month, and complete three tele-PC consultations in total over a three-to-four-month period. They will also complete self-report assessments at baseline and immediately after the last PC intervention visit, approximately 3-4 months after enrolment.
Study: NCT05759585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: person-centered lifestyle intervention
Description: Lifestyle intervention is a combined approach that encourages individuals to change their lifestyles by increasing participation in meaningful readings. This program aims to facilitate the individual's self-development of healthy routines and habits; It includes techniques such as patient education, occupational self-analysis, problem-solving, motivation generation, and implementation of behaviors to prevent and manage disease-related symptoms.
Study: NCT06342804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 2 tablets, after meals
Description: 2 tablets (256 mg), after meals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4-MUST, 2 tablets, after meals
Description: 2 tablets (256 mg), after meals
Study: NCT05128747

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DASH diet
Description: it will be face to face about the role of nutritional program to control dyslipidemia
Study: NCT05478317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECL- mPZ
Description: Flapless Technique using Piezoelectric (PZ):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. However, no flap will be reflected the osseous recontouring will be carried using special piezoelectric tip below gingival margin. The required distance between the bone crest and the gingival margin will be checked by inserting a periodontal probe into the incision below gingival margin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECL-OF
Description: Open Flap Technique (OF):~Gingivectomy and intra-sulcular incision will be carried out to remove strip of outlined marginal gingiva. Full mucoperiosteal flap will be elevated to preform ostectomy and/or osteoplasty until the desired distance achieved between the bone crest and the gingival margin. After achieving the new supracrestal distance, the flap will be sutured.
Study: NCT04756531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 1
Description: PF-07321332 Dose 1 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 2
Description: PF-07321332 Dose 2 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 3
Description: PF-07321332 Dose 3 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 4
Description: PF-07321332 Dose 4 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 5
Description: PF-07321332 Dose 5 or Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332 Dose 4 or Placebo (Fed)
Description: PF-07321332 Dose 5 or Placebo with high fat meal
Study: NCT04952714

Intervention type: DEVICE
Intervention: Oxiris
Description: Through a previously established and standardized management protocol, the treating team will prescribe renal replacement therapy by hemodiafiltration (CVVHDF) in the PrismaFlex device, at a dose of 25 mL / Kg of PrismaSate dialysis solutio and the removal filter oXiris® cytokines (Baxter) vs. the standard filter.
Study: NCT05639725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maxillary Ist premolar extraction
Description: Procedure/Surgery: Patients will undergo bilateral maxillary 1st premolars extraction before bonding followed by leveling \& alignment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SURGICAL
Description: Surgery:After leveling and alignment,placement of zygomatic miniplates in bilaterally
Study: NCT05652881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Lavage
Description: An arthrotomy will be made at the time of temporary external fixation and 1L normal saline will be used to irrigate the ankle joint.
Study: NCT04367233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia with fentanyl, propofol and remifentanil.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transverse abdominal block
Description: Transverse abdominal block with ropivacaine 0,25% 0,2 ml/kg at the end of general anesthesia with fentanyl, propofol and remifentanil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Description: At the end of general anesthesia with fentanyl, propofol and remifentanil, patients will receive quadratus lumborum block with ropivacaine 0,25% 0,2 ml/kg
Study: NCT04732143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: At least 2 weeks prior to surgery, participants will be given a Vyaire incentive spirometer device and provided with formal training on proper inspiratory muscle breathing exercise using the device. They will be instructed to perform 4 sets of these exercises per day for 14 days prior to surgery.
Study: NCT05231304

Intervention type: PROCEDURE
Intervention: Total Talus Replacement (TTR)
Description: Surgical implantation of restor3d's patient-specific custom Total Talus Replacement device.

Intervention type: PROCEDURE
Intervention: Total Ankle Total Talus Replacement (TATTR)
Description: Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device.

Intervention type: PROCEDURE
Intervention: Total Ankle Total Talus Replacement + Subtalar Fusion (TATTR + STJ)
Description: Surgical implantation of restor3d's patient-specific custom Total Ankle Total Talus Replacement (TATTR) device with concurrent subtalar fusion.

Intervention type: PROCEDURE
Intervention: Total Talus Replacement + Subtalar Fusion (TTR + STJ)
Description: Surgical implantation of restor3d's patient-specific custom Total Talus Replacement (TTR) device with concurrent subtalar fusion.
Study: NCT06445231

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Implementation of echocardiography in nursing homes
Description: An ultrasound will be carried out in the EHPAD, the result of which will be interpreted by a cardiologist then sent to the establishment and the attending physician with instructions to follow.
Study: NCT05954169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640 single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640
Description: SHR4640 single-dose
Study: NCT04300335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Exercise
Description: Supervised body weight \& resistance band resistance exercises in a one-on-one personal training setting plus home based aerobic exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Exercise
Description: Supervised body weight \& resistance band resistance exercises in a Group setting plus home based aerobic exercise
Study: NCT05167253

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
Study: NCT06157593

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: weaning from mechanical ventilator using neurally adjusted ventilatory assist
Study: NCT06305429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HabitE (effective parenting habit) program (in Brazilian Portuguese)
Description: Parents who enroll in the program will receive a series of 6 videos (\~ 7 minutes each), 1 video at a time, generally every 3 days. They will also receive daily written texts, which include implementation tips and an assessment of a target (transition) behavior.
Study: NCT06600971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupressure application
Description: The patients in the experimental group received acupressure application for a total of 8 sessions, 2 sessions per week.
Study: NCT06214468

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Acetaminophen and Nicotinamide Riboside
Description: Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Collection of urine at different time intervals following ingestion of Tylenol only

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Collection of urine at different time intervals following ingestion of Tylenol only
Study: NCT06602011

Intervention type: COMBINATION_PRODUCT
Intervention: TACE, Lenvatinib, combined with Tislelizumab group
Description: TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.
Study: NCT06597656

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Description: Therapeutic plasma exchange procedure
Study: NCT04810624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention and Changing Habits (REACH+)
Description: Psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention and Changing Habits (REACH+)
Description: Psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention and Changing Habits (REACH+)
Description: Psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relapse Prevention and Changing Habits (REACH+)
Description: Psychotherapy
Study: NCT05095428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTS Program
Description: The PARTS Program is a 16-week group intervention model of Internal Family Systems (IFS), with 8 individual IFS clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NBSR-T Program
Description: The NBSR-T Program is a 16-week nature-based group intervention model, with 8 individual non-IFS clinical sessions on a biweekly basis, developed as an attention placebo control for individuals diagnosed with PTSD.